Navigation Links
DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials

WILMINGTON, Del., and HEERLEN, Netherlands, Sept. 23 /PRNewswire-FirstCall/ -- DuPont (NYSE: DD) and Royal DSM N.V. announce an agreement to form a joint venture to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval. The joint venture will be named Actamax Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will each share a 50 percent interest.

The joint venture will address the market for surgical sealants, adhesion barriers and tissue adhesives – a large and underserved market of more than 100 million annual surgical procedures worldwide. The outcome of many surgical procedures could be positively impacted using next-generation materials under development by the joint venture.

Actamax Surgical Materials LLC will build a comprehensive biomedical product portfolio based on several patent-protected biodegradable hydrogel technologies. The early technology development was completed using DuPont materials science and biotechnology capabilities.  Commercialization will rely on the medical polymer processing and manufacturing capabilities of DSM.

The activities of the joint venture fit with the DSM biomedical materials portfolio in which the company, through its DSM Biomedical unit, has rapidly built a leading position in the past few years.  Actamax Surgical Materials LLC is a strategic component of the DuPont Applied BioSciences business, which integrates biotechnology with other sciences to create products that can transform large, addressable markets.  The joint venture will focus on the clinical validation of the products and technology, and commercialization will include manufacture and sale of proprietary products as well as the establishment of joint development relationships with leading device companies.

"Our platform of technologies will offer physicians and patients improved outcomes of surgery that will prevent post-operative complications while reducing health care costs," said John Ranieri, vice president – DuPont Applied BioSciences. "Actamax will deliver a number of products that can be optimized for different surgical situations and clinical needs. The success DSM has had in the biomedical materials market makes them an ideal strategic partner for us to commercialize our technology portfolio."

"The cooperation with DuPont is a great way to further boost our activities in the biomedical field," said Christophe J. Dardel, president – DSM Biomedical. "In line with our open innovation strategy, this will allow us to combine the strengths of two leading companies to develop solutions to better address patient needs through material innovations."

For more information, visit

Royal DSM N.V. creates solutions that nourish, protect and improve performance.  Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing.  DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about  8 billion pounds and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:

DuPont ( is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere.  Operating in more than 90 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

DSM Forward-Looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

DuPont Forward-Looking Statements

Forward-Looking Statements:  This news release contains forward-looking statements based on management's current expectations, estimates and projections.  All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements.  Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions.  These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions.  Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated.  These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
2. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
3. DuPont Provides Technology for Washington Hospital Centers Emergency Department
4. CVS Caremark Corporation Announces Quarterly Dividend
5. Dynatronics Announces Positive Year-end Results
6. Advanced Health Media Further Expands Investment in Regulatory Compliance; Company Announces Ms. Susan Y. Leonard as Chief Compliance Officer
7. Molecular Detection and Integrated Sciences Announce Distribution Agreement for Detect-Ready™ MRSA Assay in Australia
8. Neogen Corporation Announces 1st Quarter Results Conference Call
9. Precyse Solutions and M*Modal Announce Breakthrough CAC Solution
10. Chemspec International Limited Announces Share Repurchase Program
11. Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent
Post Your Comments:
(Date:11/24/2015)... -- Teledyne DALSA , a Teledyne Technologies company and ... its CMOS X-Ray detector for mammography at the ... 3, at McCormick Place in Chicago . ... imaging will be on display in the South Hall, Booth ... X-Ray detectors is the industry benchmark for high speed imaging ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
(Date:11/24/2015)... 2015   Renowned ... deliver s advice and insights on supplements ... More than 50% of Dubai ... to the DHA   femMED launches comprehensive solutions for women ... Dubai residents are not consuming enough to keep themselves ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for Tuberous Sclerosis Complex (TSC), as well as raising public awareness of the ... they need it—presented a third donation of $35,000 to bolster progress at the ...
(Date:11/25/2015)... ... 25, 2015 , ... Bunion Bootie , the newest ... of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties are ... Friday promotional pricing is in addition to any automatic discounts applied when buying ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
Breaking Medicine News(10 mins):